<DOC>
	<DOCNO>NCT01731587</DOCNO>
	<brief_summary>Phase Ib study investigate whether liposome BLP25 mucin-1 ( MUC1 ) peptide-specific immunotherapy ( L-BLP25 ) administer weekly subcutaneous dos 8 week follow single dose intravenous cyclophosphamide ( CPA ) induce reproducible cytokine pattern measure serum unresected Stage III non-small cell lung cancer ( NSCLC ) subject first-line chemo-radiation therapy .</brief_summary>
	<brief_title>Anti-cancer MUC1-specific Immunotherapy Unresectable Stage III Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>Histologically cytologically document unresectable Stage III NSCLC , define American Joint Committee Cancer/Union International Cancer Control ( AJCC/UICC ) 7th edition ( 2009 ) criterion . All histological subtypes acceptable , include bronchioalveolar carcinoma Documented stable disease objective response , accord Response Evaluation Criteria In Solid Tumors ( RECIST ) Version 1.0 , primary chemoradiotherapy ( either sequential concomitant ) unresected Stage III disease , within 4 week ( 28 day ) prior enrollment Receipt concomitant sequential chemoradiotherapy , consist minimum two cycle platinumbased chemotherapy minimum radiation dose great equal 50 Gray . Subjects must complete primary thoracic chemoradiotherapy least 4 week ( 28 day ) later 84 day prior enrollment . Subjects receive prophylactic brain irradiation part primary chemoradiotherapy eligible Platelet count great equal 140 * 10^9 per liter , white blood cell ( WBC ) great equal 2.5 * 10^9 per liter , hemoglobin great equal 90 gram per liter Eastern Cooperative Oncology Group performance status ( ECOG PS ) 01 Additional Inclusion Criteria apply Pretherapies : Previous lung cancer specific therapy ( include surgery ) primary chemoradiotherapy Receipt immunotherapy within 4 week ( 28 day ) prior enrollment . Note : Subjects receive monoclonal antibody image acceptable Receipt investigational systemic drug ( include offlabel use approve product ) within 4 week ( 28 day ) prior enrollment Disease status : Metastatic disease Malignant pleural effusion initial diagnosis and/or trial entry Past current history neoplasm lung carcinoma , except curatively treat nonmelanoma skin cancer , situ carcinoma cervix cancer curatively treat evidence disease least 5 year Autoimmune disease A recognized immunodeficiency disease include cellular immunodeficiency , hypogammaglobulinemia dysgammaglobulinemia ; subject hereditary congenital immunodeficiency Any preexist medical condition require systemic chronic steroid immunosuppressive therapy ( steroids treatment radiation pneumonitis allow ) Known Hepatitis B and/or C Active infection enrollment , include limited , flulike infection , urinary tract infection , bronchopulmonary infection , etc Physiological function : Clinically significant hepatic dysfunction ( , alanine aminotransferase [ ALT ] great 2.5 time normal upper limit [ ULN ] ; aspartate aminotransferase [ AST ] great 2.5 time ULN ; bilirubin great equal 1.5 * ULN ) Clinically significant renal dysfunction ( , serum creatinine great equal 1.5 * ULN ) Clinically significant cardiac disease , example , New York Heart Association ( NYHA ) Classes IIIIV ; uncontrolled angina , uncontrolled arrhythmia uncontrolled hypertension , myocardial infarction previous 6 month confirm electrocardiogram ( ECG ) Splenectomy Infectious process opinion investigator could compromise subject 's ability mount immune response Additional Exclusion Criteria apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Non-small cell lung cancer ( NSCLC )</keyword>
	<keyword>exploratory study</keyword>
	<keyword>L-BLP25</keyword>
</DOC>